General Biotechnology

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s a strategic playbook. And the most important part isn’t the headlines about approvals or launches. It’s the patent pipeline behind them: the quiet, methodical work that determines who can compete, …

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

General Biotechnology

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The drug patent clock is ticking—most IP teams are forecasting it with the wrong instrument.
In pharma, timing isn’t just strategy—it’s value. A few months can decide whether a blockbuster stays protected, whether a generic launch triggers price erosio…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

General Biotechnology

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors

Pharma strategy is often built on what’s known—trial readouts, competitor pipelines, formulary wins. But the real advantage is usually created by what’s about to become knowable: when a product’s exclusivity is about to end, when a patent landscape shi…

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors Read Post »

Biotechblog
Scroll to Top